Nonaspirin nonsteroidal anti‐inflammatory drugs and gastric cancer risk after Helicobacter pylori eradication: A territory‐wide study
- 20 January 2021
- Vol. 127 (11) , 1805-1815
Abstract
Background: Despite Helicobacter pylori (HP) eradication, individuals can still develop gastric cancer (GC). Prior studies have demonstrated that nonaspirin nonsteroidal anti‐inflammatory drugs (NA‐NSAIDs) reduce the risk of GC, but this may be caused by immortal time bias and failure to adjust for HP status. The objective of this study was to investigate whether NA‐NSAIDs reduced the risk of GC in patients who undergo H. pylori eradication.Methods: Adult patients who had received clarithromycin‐based triple therapy between 2003 and 2016 were identified from a territory‐wide health care database. Exclusion criteria included prior GC or GC diagnosed <6 months after HP eradication, prior gastrectomy, gastric ulcer after HP eradication, and failure of triple therapy. Covariates included age, sex, prior peptic ulcer disease, other comorbidities, and concurrent medications (aspirin, proton pump inhibitors, statins, and metformin). To avoid immortal time bias, NA‐NSAID use (≥90 days) was treated as a time‐dependent variable in a multivariable Cox model (time‐dependent analysis). Time‐independent analysis was also performed.Results: During a median follow‐up of 8.9 years (interquartile range, 5.4‐12.6 years), 364 of 92,017 patients (0.4%) who underwent HP eradication developed GC. NA‐NSAID use was associated with a significant reduction in the risk of GC in time‐fixed analysis (adjusted hazard ratio [aHR], 0.65; 95% CI, 0.47‐0.90), but not in time‐dependent multivariable analysis (aHR, 1.35; 95% CI, 0.97‐1.87). Time‐dependent subgroup analyses also did not indicate any significant association between NA‐NSAID use and either cardia GC (aHR, 0.75; 95% CI, 0.27‐2.06) or noncardia GC (aHR, 1.28; 95% CI, 0.83‐1.98).Conclusions: NA‐NSAID use was not associated with a reduced risk of GC among patients who underwent HP eradication. The chemopreventive effect of NA‐NSAIDs observed in prior studies may have been confounded by immortal time bias.Keywords
This publication has 55 references indexed in Scilit:
- Helicobacter pylori-induced gastric inflammation and gastric cancerCancer Letters, 2014
- Familial gastric cancer: detection of a hereditary cause helps to understand its etiologyHereditary Cancer in Clinical Practice, 2012
- Nonsteroidal Anti-inflammatory Drug Use Reduces Risk of Adenocarcinomas of the Esophagus and Esophagogastric Junction in a Pooled AnalysisGastroenterology, 2012
- Nonsteroidal Antiinflammatory Drugs and Risk of Gastric Adenocarcinoma: The Multiethnic Cohort StudyAmerican Journal of Epidemiology, 2009
- Proton pump inhibitors and risk of gastric cancer: a population-based cohort studyBritish Journal of Cancer, 2009
- Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysisBritish Journal of Cancer, 2009
- Survival End Point Reporting in Randomized Cancer Clinical Trials: A Review of Major JournalsJournal of Clinical Oncology, 2008
- Use of Anti-Inflammatory Drugs and Lower Esophageal Sphincter–Relaxing Drugs and Risk of Esophageal and Gastric CancersClinical Gastroenterology and Hepatology, 2007
- Inflammation, atrophy, and gastric cancerJournal of Clinical Investigation, 2007
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983